

Rupert Handgretinger

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10172115/publications.pdf>

Version: 2024-02-01

175
papers

5,057
citations

101543

36
h-index

102487

66
g-index

180
all docs

180
docs citations

180
times ranked

6943
citing authors

#	ARTICLE	IF	CITATIONS
1	Two-cavities approach for resection of pediatric abdominal neuroblastic tumors: experience of a national reference pediatric onco-surgical center. <i>Journal of Cancer Research and Clinical Oncology</i> , 2023, 149, 1485-1493.	2.5	3
2	Blinatumomab in pediatric relapsed/refractory B-cell acute lymphoblastic leukemia: RIALTO expanded access study final analysis. <i>Blood Advances</i> , 2022, 6, 1004-1014.	5.2	22
3	A Prospective, Multicenter Study of Closed System Extracorporeal Photopheresis for Children With Steroid-Refractory Acute Graft-Versus-Host Disease. <i>Transplantation and Cellular Therapy</i> , 2022, , .	1.2	3
4	A Mutation-Agnostic Hematopoietic Stem Cell Gene Therapy for Metachromatic Leukodystrophy. <i>CRISPR Journal</i> , 2022, 5, 66-79.	2.9	8
5	Long-Term Clinical Outcome and Prognostic Factors of Children and Adolescents with Localized Rhabdomyosarcoma Treated on the CWS-2002P Protocol. <i>Cancers</i> , 2022, 14, 899.	3.7	14
6	D,L-Methadone enhances the cytotoxic activity of standard chemotherapeutic agents on pediatric rhabdomyosarcoma. <i>Journal of Cancer Research and Clinical Oncology</i> , 2022, , 1.	2.5	0
7	Hematopoietic Stem Cell Transplantation with Mesenchymal Stromal Cells in Children with Metachromatic Leukodystrophy. <i>Stem Cells and Development</i> , 2022, 31, 163-175.	2.1	6
8	Results of a multicenter phase I/II trial of TCR $\alpha\beta$ and CD19-depleted haploidentical hematopoietic stem cell transplantation for adult and pediatric patients. <i>Bone Marrow Transplantation</i> , 2022, 57, 423-430.	2.4	27
9	Somatic Reversion of a Novel IL2RG Mutation Resulting in Atypical X-Linked Combined Immunodeficiency. <i>Genes</i> , 2022, 13, 35.	2.4	8
10	Could (should) we abandon total body irradiation for conditioning in children with leukemia. <i>Blood Reviews</i> , 2022, 56, 100966.	5.7	2
11	Metronomic oral maintenance chemotherapy in patients with localized high-risk rhabdomyosarcoma (RMS) and RMS-like tumors: A report from a randomized, multicenter, phase III trial CWS-2007HR.. <i>Journal of Clinical Oncology</i> , 2022, 40, 10033-10033.	1.6	2
12	Matched versus Haploidentical Hematopoietic Stem Cell Transplantation as Treatment Options for Primary Immunodeficiencies in Children. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 71.e1-71.e12.	1.2	6
13	A case series of children and young people admitted to a tertiary care hospital in Germany with COVID-19. <i>BMC Infectious Diseases</i> , 2021, 21, 133.	2.9	14
14	Arginase 1 polymorphonuclear myeloid-derived suppressor cells are elevated in patients with active pemphigus and correlate with an increased Th2/Th1 response. <i>Experimental Dermatology</i> , 2021, 30, 782-791.	2.9	4
15	Long-Term Follow-Up After the Application of Mesenchymal Stromal Cells in Children and Adolescents with Steroid-Refractory Graft-Versus-Host Disease. <i>Stem Cells and Development</i> , 2021, 30, 234-246.	2.1	6
16	Mesenchymal Stem Cell Therapy for Severe COVID-19 ARDS. <i>Journal of Intensive Care Medicine</i> , 2021, 36, 681-688.	2.8	47
17	Universal Gene Correction Approaches for β -hemoglobinopathies Using CRISPR-Cas9 and Adeno-Associated Virus Serotype 6 Donor Templates. <i>CRISPR Journal</i> , 2021, 4, 207-222.	2.9	6
18	Removal of CD276+ cells from haploidentical memory T-cell grafts significantly lowers the risk of GVHD. <i>Bone Marrow Transplantation</i> , 2021, 56, 2336-2354.	2.4	2

#	ARTICLE	IF	CITATIONS
19	Fulminant <i>Rhizomucor pusillus</i> mucormycosis during anti-leukemic treatment with blinatumomab in a child: A case report and review of the literature. <i>Medical Mycology Case Reports</i> , 2021, 32, 4-9.	1.3	8
20	Prevalence of SARS-CoV-2 Infection in Children and Their Parents in Southwest Germany. <i>JAMA Pediatrics</i> , 2021, 175, 586.	6.2	124
21	Myeloid-Derived Suppressor Cells Dampen Airway Inflammation Through Prostaglandin E2 Receptor 4. <i>Frontiers in Immunology</i> , 2021, 12, 695933.	4.8	13
22	Immunomonitoring of Stage IV Relapsed Neuroblastoma Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplantation and Subsequent GD2 (ch14.18/CHO) Antibody Treatment. <i>Frontiers in Immunology</i> , 2021, 12, 690467.	4.8	10
23	Hematopoietic Stem Cell Transplantation for Patients with Autosomal Recessive Complete $\text{INF-}\gamma$ Receptor 2 Deficiency: Experience in Oman. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 881.e1-881.e5.	1.2	3
24	Introducing isotonic fluids into pediatric oncology. <i>Pediatric Hematology and Oncology</i> , 2021, , 1-8.	0.8	1
25	Novel adapter CAR-T cell technology for precisely controllable multiplex cancer targeting. <i>Oncolmmunology</i> , 2021, 10, .	4.6	16
26	The European Society for Blood and Marrow Transplantation (EBMT) consensus recommendations for donor selection in haploidentical hematopoietic cell transplantation. <i>Bone Marrow Transplantation</i> , 2020, 55, 12-24.	2.4	94
27	Hematopoietic stem cell transplantation for children with acute myeloid leukemia—results of the AML SCT-BFM 2007 trial. <i>Leukemia</i> , 2020, 34, 613-624.	7.2	19
28	Systemic antitumor effect by regional hyperthermia combined with low-dose chemotherapy and immunologic correlates in an adolescent patient with rhabdomyosarcoma — a case report. <i>International Journal of Hyperthermia</i> , 2020, 37, 55-65.	2.5	8
29	Hematopoietic stem cell gene therapy: The optimal use of lentivirus and gene editing approaches. <i>Blood Reviews</i> , 2020, 40, 100641.	5.7	14
30	GD2-targeted chimeric antigen receptor T cells prevent metastasis formation by elimination of breast cancer stem-like cells. <i>Oncolmmunology</i> , 2020, 9, 1683345.	4.6	54
31	<p>>Antiemetic Prophylaxis with Fosaprepitant and 5-HT₃-Receptor Antagonists in Pediatric Patients Undergoing Autologous Hematopoietic Stem Cell Transplantation</p>. <i>Drug Design, Development and Therapy</i> , 2020, Volume 14, 3915-3927.	4.3	1
32	Defibrotide for the Treatment of Pediatric Inflammatory Multisystem Syndrome Temporally Associated With Severe Acute Respiratory Syndrome Coronavirus 2 Infection in 2 Pediatric Patients. <i>Journal of the Pediatric Infectious Diseases Society</i> , 2020, 9, 622-625.	1.3	13
33	Blinatumomab in pediatric patients with relapsed/refractory acute lymphoblastic leukemia: results of the RIALTO trial, an expanded access study. <i>Blood Cancer Journal</i> , 2020, 10, 77.	6.2	65
34	Establishment and Characterization of a Sclerosing Spindle Cell Rhabdomyosarcoma Cell Line with a Complex Genomic Profile. <i>Cells</i> , 2020, 9, 2668.	4.1	4
35	Comparative analysis of lentiviral gene transfer approaches designed to promote fetal hemoglobin production for the treatment of β^2 -hemoglobinopathies. <i>Blood Cells, Molecules, and Diseases</i> , 2020, 84, 102456.	1.4	2
36	Comparative targeting analysis of KLF1, BCL11A, and HBG1/2 in CD34+ HSPCs by CRISPR/Cas9 for the induction of fetal hemoglobin. <i>Scientific Reports</i> , 2020, 10, 10133.	3.3	38

#	ARTICLE	IF	CITATIONS
37	RNA ImmunoGenic Assay: Simple method for detecting immunogenicity of in vitro transcribed mRNA. <i>Advances in Cell and Gene Therapy</i> , 2020, 3, e79.	0.9	2
38	Antiemetic prophylaxis with fosaprepitant and granisetron in pediatric patients undergoing allogeneic hematopoietic stem cell transplantation. <i>Journal of Cancer Research and Clinical Oncology</i> , 2020, 146, 1089-1100.	2.5	3
39	Clinical applications of donor lymphocyte infusion from an HLA-haploidentical donor: consensus recommendations from the Acute Leukemia Working Party of the EBMT. <i>Haematologica</i> , 2020, 105, 47-58.	3.5	51
40	Safety and Efficacy of CTX001 in Patients with Transfusion-Dependent β^2 -Thalassemia and Sickle Cell Disease: Early Results from the Climb THAL-111 and Climb SCD-121 Studies of Autologous CRISPR-CAS9-Modified CD34+ Hematopoietic Stem and Progenitor Cells. <i>Blood</i> , 2020, 136, 3-4.	1.4	34
41	Blinatumomab in Children with Relapsed or Refractory B-Precursor Acute Lymphoblastic Leukemia (R/R-ALL): Final Results of 110 Patients Treated in an Expanded Access Study (RIALTO). <i>Blood</i> , 2020, 136, 24-25.	1.4	2
42	Interaction of arsenic trioxide and etoposide in Ewing sarcoma cell lines. <i>Oncology Reports</i> , 2020, 43, 337-345.	2.6	3
43	RNA ImmunoGenic Assay: A Method to Detect Immunogenicity of in vitro Transcribed mRNA in Human Whole Blood. <i>Bio-protocol</i> , 2020, 10, e3850.	0.4	2
44	Transplantation for Congenital Sideroblastic Anaemia Is Feasible and Offers Outcomes Comparable to Other Transfusion Dependent Anaemias. a Joint Retrospective Study of the Paediatric Diseases and Severe Aplastic Anaemia Working Parties (PDWP/SAAWP) of EBMT. <i>Blood</i> , 2020, 136, 45-47.	1.4	0
45	Favorable immune recovery and low rate of GvHD in children transplanted with partially T cell-depleted PBSC grafts. <i>Bone Marrow Transplantation</i> , 2019, 54, 53-62.	2.4	3
46	LMO2 activation by deacetylation is indispensable for hematopoiesis and T-ALL leukemogenesis. <i>Blood</i> , 2019, 134, 1159-1175.	1.4	20
47	Ex vivo expansion of autologous, donor-derived NK-, $\gamma\delta$ T-, and cytokine induced killer (CIK) cells post haploidentical hematopoietic stem cell transplantation results in increased antitumor activity. <i>Bone Marrow Transplantation</i> , 2019, 54, 727-732.	2.4	5
48	The German National Registry of Primary Immunodeficiencies (2012–2017). <i>Frontiers in Immunology</i> , 2019, 10, 1272.	4.8	71
49	Low mutational load in pediatric medulloblastoma still translates into neoantigens as targets for specific T-cell immunotherapy. <i>Cytotherapy</i> , 2019, 21, 973-986.	0.7	25
50	Invariant NKT Cells From Donor Lymphocyte Infusions (DLI-iNKTs) Promote ex vivo Lysis of Leukemic Blasts in a CD1d-Dependent Manner. <i>Frontiers in Immunology</i> , 2019, 10, 1542.	4.8	11
51	Allogeneic hematopoietic stem cell transplantation in two brothers with DNA ligase IV deficiency: a case report and review of the literature. <i>BMC Pediatrics</i> , 2019, 19, 346.	1.7	8
52	Efficacy, Safety And Feasibility Of Antiemetic Prophylaxis With Fosaprepitant, Granisetron And Dexamethasone In Pediatric Patients With Hemato-Oncological Malignancies. <i>Drug Design, Development and Therapy</i> , 2019, Volume 13, 3439-3451.	4.3	5
53	ADCC can improve graft vs leukemia effect after T- and B-cell depleted haploidentical stem cell transplantation in pediatric B-lineage ALL. <i>Bone Marrow Transplantation</i> , 2019, 54, 689-693.	2.4	5
54	Fast enzymatic synthesis of n.c.a. ^{18}F fluorodopamine (FDA) from n.c.a. ^{18}F FDOPA and the fate of ^{18}F FDOPA and ^{18}F FDA in neuroblastoma and Caki cells after their uptake. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2019, 62, 438-447.		5

#	ARTICLE	IF	CITATIONS
55	CRISPR/Cas9-modified hematopoietic stem cellsâ€”present and future perspectives for stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2019, 54, 1940-1950.	2.4	26
56	CSF administration prior to donor lymphocyte apheresis promotes anti-leukaemic effects in allogeneic HCT patients. <i>British Journal of Haematology</i> , 2019, 186, 60-71.	2.5	27
57	Biological treatment of pediatric sarcomas by combined virotherapy and NK cell therapy. <i>BMC Cancer</i> , 2019, 19, 1172.	2.6	21
58	Childhood supratentorial ependymomas with <i>YAP1</i> â€MAML1 fusion: an entity with characteristic clinical, radiological, cytogenetic and histopathological features. <i>Brain Pathology</i> , 2019, 29, 205-216.	4.1	75
59	Blinatumomab in Pediatric Patients with Relapsed/Refractory B-Cell Precursor and Molecularly Resistant Acute Lymphoblastic Leukemia (R/R ALL): Updated Analysis of 110 Patients Treated in an Expanded Access Study (RIALTO). <i>Blood</i> , 2019, 134, 1294-1294.	1.4	7
60	Use of Ex Vivo Graft Manipulation and Posttransplant Cyclophosphamide Result in Low GvHD Rates and Acceptable Engraftment after RIC Regimens in Pediatric Mismatched SCT. <i>Blood</i> , 2019, 134, 3255-3255.	1.4	0
61	Germline Genetic IKZF1 Variation and Predisposition to Childhood Acute Lymphoblastic Leukemia. <i>Cancer Cell</i> , 2018, 33, 937-948.e8.	16.8	142
62	Association analysis between SUFU polymorphism rs17114808 and acute graft versus host disease after hematopoietic stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2018, 53, 377-382.	2.4	6
63	The potential role of γ T cells after allogeneic HCT for leukemia. <i>Blood</i> , 2018, 131, 1063-1072.	1.4	94
64	The European Society for Blood and Marrow Transplantation (EBMT) Consensus Guidelines for the Detection and Treatment of Donor-specific Anti-HLA Antibodies (DSA) in Haploidentical Hematopoietic Cell Transplantation. <i>Bone Marrow Transplantation</i> , 2018, 53, 521-534.	2.4	168
65	Haploidentical Stem Cell Transplantation for Refractory/Relapsed Neuroblastoma. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1005-1012.	2.0	55
66	CD34 ⁺ selected stem cell boosts can improve poor graft function after paediatric allogeneic stem cell transplantation. <i>British Journal of Haematology</i> , 2018, 180, 90-99.	2.5	39
67	Gene correction of HBB mutations in CD34+ hematopoietic stem cells using Cas9 mRNA and ssODN donors. <i>Molecular and Cellular Pediatrics</i> , 2018, 5, 9.	1.8	49
68	Immune monitoring and TCR sequencing of CD4 T cells in a long term responsive patient with metastasized pancreatic ductal carcinoma treated with individualized, neoepitope-derived multipptide vaccines: a case report. <i>Journal of Translational Medicine</i> , 2018, 16, 23.	4.4	30
69	Characterization of monocyte subtypes regarding their phenotype and development in the context of graft-versus-host disease. <i>Transplant Immunology</i> , 2018, 50, 48-54.	1.2	8
70	High Molecular Remission Rate in Pediatric Patients (pts) with Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (r/r ALL) Treated with Blinatumomab: Rialto an Open-Label, Multicenter, Expanded Access Study. <i>Blood</i> , 2018, 132, 1375-1375.	1.4	3
71	Results of a Prospective, Multicenter, Phase I/II Clinical Study in Pediatric and Adult Patients Using TCR Alpha/Beta and CD19 Depleted Haploidentical Hematopoietic Stem Cell Grafts Following Reduced-Intensity Conditioning. <i>Blood</i> , 2018, 132, 604-604.	1.4	3
72	Combinatorial Targeting of Multiple Shared Antigens By Adapter-CAR-T Cells (aCAR-Ts) Allows Target Cell Discrimination and Specific Lysis Based on Differential Expression Profiles. <i>Blood</i> , 2018, 132, 4543-4543.	1.4	8

#	ARTICLE	IF	CITATIONS
73	Emerging role of immunotherapy for childhood cancers. <i>Chinese Clinical Oncology</i> , 2018, 7, 14-14.	1.2	8
74	Prophylaxis of Chemotherapy-Induced Nausea and Vomiting with Fosaprepitant and Granisetron in Pediatric Patients after Allogeneic HSCT. <i>Blood</i> , 2018, 132, 3388-3388.	1.4	0
75	Invariant Natural Killer T Cells from Donor Lymphocyte Infusions (DLI-iNKTs) Contribute to Anti-Tumor Immunity after Allogeneic Hematopoietic Cell Transplantation. <i>Blood</i> , 2018, 132, 3340-3340.	1.4	0
76	Tumor-priming converts NK cells to memory-like NK cells. <i>Oncolmmunology</i> , 2017, 6, e1317411.	4.6	28
77	Tumor-targeted IL-12 combined with local irradiation leads to systemic tumor control via abscopal effects <i>in vivo</i> . <i>Oncolmmunology</i> , 2017, 6, e1323161.	4.6	39
78	Outcome of children with acute leukemia given HLA-haploidentical HSCT after $\hat{1}\hat{1}^2$ T-cell and B-cell depletion. <i>Blood</i> , 2017, 130, 677-685.	1.4	261
79	Enzymatic characterization of novel arylsulfatase A variants using human arylsulfatase A-deficient immortalized mesenchymal stromal cells. <i>Human Mutation</i> , 2017, 38, 1511-1520.	2.5	20
80	Increase of Intermediate Monocytes in Graft-versus-Host Disease: Correlation with MDR1+Th17.1 Levels and the Effect of Prednisolone and $1\hat{1}\pm,25$ -Dihydroxyvitamin D3. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 2057-2064.	2.0	13
81	Expression of KIR2DS1 does not significantly contribute to NK cell cytotoxicity in HLA-C1/C2 heterozygous haplotype B donors. <i>International Immunology</i> , 2017, 29, 423-429.	4.0	5
82	Transcriptomic profile of cystic fibrosis patients identifies type I interferon response and ribosomal stalk proteins as potential modifiers of disease severity. <i>PLoS ONE</i> , 2017, 12, e0183526.	2.5	23
83	Immunotargeting relapsed or refractory precursor B-cell acute lymphoblastic leukemia – role of blinatumomab. <i>OncoTargets and Therapy</i> , 2017, Volume 10, 3567-3578.	2.0	14
84	Blinatumomab use in pediatric patients (pts) with relapsed/refractory B-precursor acute lymphoblastic leukemia (r/r ALL) from an open-label, multicenter, expanded access study.. <i>Journal of Clinical Oncology</i> , 2017, 35, 10530-10530.	1.6	6
85	Combined application of arsenic trioxide and lithium chloride augments viability reduction and apoptosis induction in human rhabdomyosarcoma cell lines. <i>PLoS ONE</i> , 2017, 12, e0178857.	2.5	10
86	Treatment of graft failure with $\langle\text{sc}\rangle\text{TNI}\langle/\text{sc}\rangle$ -based reconditioning and haploidentical stem cells in paediatric patients. <i>British Journal of Haematology</i> , 2016, 175, 115-122.	2.5	29
87	Reduction of Minimal Residual Disease in Pediatric B-lineage Acute Lymphoblastic Leukemia by an Fc-optimized CD19 Antibody. <i>Molecular Therapy</i> , 2016, 24, 1634-1643.	8.2	18
88	Enhanced binding of necrosis-targeting immunocytokine NHS-IL12 after local tumour irradiation in murine xenograft models. <i>Cancer Immunology, Immunotherapy</i> , 2016, 65, 1003-1013.	4.2	26
89	Exploitation of natural killer cells for the treatment of acute leukemia. <i>Blood</i> , 2016, 127, 3341-3349.	1.4	130
90	Phase I/Phase II Study of Blinatumomab in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia. <i>Journal of Clinical Oncology</i> , 2016, 34, 4381-4389.	1.6	478

#	ARTICLE	IF	CITATIONS
91	Improved selectivity of mIBG uptake into neuroblastoma cells in vitro and in vivo by inhibition of organic cation transporter 3 uptake using clinically approved corticosteroids. <i>Nuclear Medicine and Biology</i> , 2016, 43, 543-551.	0.6	11
92	Arsenic trioxide potentiates the effectiveness of etoposide in Ewing sarcomas. <i>International Journal of Oncology</i> , 2016, 49, 2135-2146.	3.3	8
93	Collagen VII Half-Life at the Dermal-Epidermal Junction Zone: Implications for Mechanisms and Therapy of Genodermatoses. <i>Journal of Investigative Dermatology</i> , 2016, 136, 1116-1123.	0.7	38
94	Targeting hedgehog signalling by arsenic trioxide reduces cell growth and induces apoptosis in rhabdomyosarcoma. <i>International Journal of Oncology</i> , 2016, 48, 801-812.	3.3	24
95	TCR-Alpha/Beta and CD19 Depleted Haploidentical Stem Cell Transplantation Following Reduced Intensity Conditioning in Children: First Results of a Prospective Multicenter Phase I/II Clinical Trial. <i>Blood</i> , 2016, 128, 389-389.	1.4	11
96	Germline Genetic Variation in IKZF1 and Predisposition to Childhood Acute Lymphoblastic Leukemia. <i>Blood</i> , 2016, 128, LBA-2-LBA-2.	1.4	3
97	ZUMA-4: A phase 1/2 multicenter study evaluating the safety and efficacy of KTE-C19 (anti-CD19 CAR T) Tj ETQq1 leukemia (r/r ALL).. <i>Journal of Clinical Oncology</i> , 2016, 34, TPS7075-TPS7075.	1.0784314 1.6	3
98	Correlation between positron emission tomography and Cerenkov luminescence imaging <i>in vivo</i> and <i>ex vivo</i> using ⁶⁴ Cu-labeled antibodies in a neuroblastoma mouse model. <i>Oncotarget</i> , 2016, 7, 67403-67411.	1.8	11
99	Decentralized Manufacture of TCR-Alpha/Beta and CD19 Depleted Haploidentical Stem Cell Grafts for Children within a Multicenter Phase I/II Clinical Trial. <i>Blood</i> , 2016, 128, 2172-2172.	1.4	0
100	No association between the presence of killer-cell immunoglobulin-like receptor genes and susceptibility to childhood ALL. <i>Blood</i> , 2015, 125, 3355-3357.	1.4	4
101	NKG2D Signaling Leads to NK Cell Mediated Lysis of Childhood AML. <i>Journal of Immunology Research</i> , 2015, 2015, 1-10.	2.2	26
102	Arabinoxylan rice bran (MGN-3/Biobran) enhances natural killer cell-mediated cytotoxicity against neuroblastoma <i>in vitro</i> and <i>in vivo</i> . <i>Cytotherapy</i> , 2015, 17, 601-612.	0.7	57
103	Cancer-targeted IL-12 controls human rhabdomyosarcoma by senescence induction and myogenic differentiation. <i>Oncolmmunology</i> , 2015, 4, e1014760.	4.6	49
104	Chronic graft-versus-host-disease in CD34+humanized NSG mice is associated with human susceptibility HLA haplotypes for autoimmune disease. <i>Journal of Autoimmunity</i> , 2015, 62, 55-66.	6.5	38
105	High Local Concentrations of Intra dermal MSCs Restore Skin Integrity and Facilitate Wound Healing in Dystrophic Epidermolysis Bullosa. <i>Molecular Therapy</i> , 2015, 23, 1368-1379.	8.2	64
106	Adoptive T-cell therapy with hexon-specific Th1 cells as a treatment of refractory adenovirus infection after HSCT. <i>Blood</i> , 2015, 125, 1986-1994.	1.4	127
107	Rapid generation of NY-ESO-1-specific CD4 ⁺ T _H 1 cells for adoptive T-cell therapy. <i>Oncolmmunology</i> , 2015, 4, e1002723.	4.6	20
108	Preemptive administration of human α T cell receptor-targeting monoclonal antibody GZ-1 α TCR potently abrogates aggressive graft-versus-host disease in vivo. <i>Annals of Hematology</i> , 2015, 94, 1907-1919.	1.8	6

#	ARTICLE	IF	CITATIONS
127	Fetomaternal Microchimerism Is Associated with Better Outcome in Haploidentical Hematopoietic Stem Cell Transplantation. <i>Blood</i> , 2014, 124, 1242-1242.	1.4	2
128	Which patients with rhabdomyosarcoma (RMS) do need radiotherapy (RTX)? The long-term results of the CWS studies -81, -86, -91, and -96.. <i>Journal of Clinical Oncology</i> , 2014, 32, 10005-10005.	1.6	0
129	NY-ESO-1 specific CD4 ⁺ T _h 1 cells for immunotherapy of cancer.. <i>Journal of Clinical Oncology</i> , 2014, 32, 3071-3071.	1.6	0
130	Transfer of Ex Vivo Expanded NK and $\gamma\delta$ T Cells from Untouched Posttransplant PBMCs to Clear Minimal Residual Disease in Acute Myeloid Leukemia. <i>Blood</i> , 2014, 124, 5294-5294.	1.4	0
131	Improved Immune Recovery after Transplantation of TCR $\alpha\beta$ /CD19 Depleted Allografts from Haploidentical Donors in Pediatric Patients. <i>Blood</i> , 2014, 124, 852-852.	1.4	0
132	Interventional Intensification of Chemotherapy Prior to Hematopoietic Stem Cell Transplantation Reduces Residual Leukemia but Does Not Improve Survival in Children with Relapsed Acute Lymphoblastic Leukemia. <i>Blood</i> , 2014, 124, 61-61.	1.4	1
133	CD133-Positive Hematopoietic Stem Cells: From Biology to Medicine. <i>Advances in Experimental Medicine and Biology</i> , 2013, 777, 99-111.	1.6	34
134	Alternative Donor Stem Cell Transplantation In Aplastic Anemias and Refractory Cytopenias Is Safe and Feasible With T- and B-Cell Depleted Haploidentical Grafts. <i>Blood</i> , 2013, 122, 4573-4573.	1.4	1
135	Negative depletion of CD3 ⁺ and TcR $\alpha\beta$ ⁺ T cells. <i>Current Opinion in Hematology</i> , 2012, 19, 434-439.	2.5	73
136	New Approaches to Graft Engineering for Haploidentical Bone Marrow Transplantation. <i>Seminars in Oncology</i> , 2012, 39, 664-673.	2.2	72
137	A New Dosing Scheme of ATG-F Prevents Rejection and Maintains Immune Recovery in Haploidentical T and B Cell Depleted Stem Cell Transplantation. <i>Blood</i> , 2012, 120, 4154-4154.	1.4	1
138	KIR Haplotype B Donors but Not KIR-Ligand Mismatch Result in a Reduced Risk of Relapse After Haploidentical Hematopoietic Stem Cell Transplantation Using Reduced Intensity Conditioning and a CD3/CD19 Depleted Graft.. <i>Blood</i> , 2012, 120, 3101-3101.	1.4	0
139	Detection of Th1 Driven T-Cell Responses in Peripheral Blood Could Guide Individualized Immunosuppression and Risk of Viral Reactivation Under GvHD Prophylaxis Following Allogeneic Stem Cell Transplantation.. <i>Blood</i> , 2012, 120, 3047-3047.	1.4	0
140	Use of a Fc-Optimized CD19 Antibody for Treatment of MRD in Pediatric Patients with B-Lineage Acute Lymphoblastic Leukemia. <i>Blood</i> , 2012, 120, 581-581.	1.4	6
141	Flow Cytometry Based Chimerism Analysis Can Predict Graft Rejection in Pediatric Patients Receiving HLA Mismatched Stem Cell Transplantation. <i>Blood</i> , 2012, 120, 4156-4156.	1.4	0
142	Transplantation of TcR $\alpha\beta$ /CD19 Depleted Stem Cells From Haploidentical Donors: Robust Engraftment and Rapid Immune Reconstitution In Children with High Risk Leukemia. <i>Blood</i> , 2011, 118, 1005-1005.	1.4	9
143	Reduced Risk of Relapse In Pediatric ALL After Haploidentical Transplantation of T-Cell Depleted Grafts From KIR Haplotype B Donors,. <i>Blood</i> , 2011, 118, 4133-4133.	1.4	0
144	NK Cell Activity Influences Long Term Outcome of Pediatric Leucemias After T Cell Depleted Stem Cell Transplantation,. <i>Blood</i> , 2011, 118, 4141-4141.	1.4	0

#	ARTICLE	IF	CITATIONS
145	Use of IL15 Stimulated, CD3/19 Depleted Transplants From Haploidentical Donors In Pediatric Malignancies. <i>Blood</i> , 2010, 116, 3548-3548.	1.4	0
146	Transient but Reversible Activation Defect of T-Cell Responses Against Cytomegalovirus and Adenovirus through Immunosuppression with Calcineurin Inhibitors.. <i>Blood</i> , 2010, 116, 4542-4542.	1.4	0
147	Safety and Feasibility of Posaconazole as Oral Antifungal Prophylaxis In Pediatric Patients Under 12 Years of Age Following Allogeneic Stem Cell Transplantation.. <i>Blood</i> , 2010, 116, 1308-1308.	1.4	5
148	Allogeneic Hematopoietic Stem Cell Transplantation (SCT) In Children with ALL: Outcome of Matched Sibling Donor SCT (MSD-SCT) Is Equivalent to Unrelated Well Matched Donor HSCT (MD-HSCT) A Report From the Prospective International Multicenter Trial ALL-SCT-BFM 2003. <i>Blood</i> , 2010, 116, 530-530.	1.4	0
149	Effect of the HDAC Inhibitor SAHA on the Immunomodulatory Properties of MSC and Tumor Stroma Cells.. <i>Blood</i> , 2010, 116, 2592-2592.	1.4	1
150	Haploidentical Stem Cell Transplantation for Children with High-Risk Leukemia In Chile: Report of the First 15 Cases.. <i>Blood</i> , 2010, 116, 4581-4581.	1.4	0
151	Patterns of HLA-DR Surface Expression on CD14+ Monocytes During Adverse Events After Hematopoietic Stem Cell Transplantation.. <i>Blood</i> , 2010, 116, 1499-1499.	1.4	0
152	Adoptive Transfer of EBNA1-Specific T-Cells as a Treatment of Epstein-Barr-Virus Reactivation Following Allogeneic Stem Cell Transplantation. <i>Blood</i> , 2010, 116, 2342-2342.	1.4	0
153	Results of a Phase II Study of Haploidentical Hematopoietic Cell Transplantation (HHCT) in Adults Using Reduced Intensity Conditioning and CD3/CD19-Depleted Grafts: Clinical Outcome and Immune Reconstitution.. <i>Blood</i> , 2009, 114, 1203-1203.	1.4	0
154	High Progenitor Cell Frequency at Diagnosis Predicts High Minimal residual Disease Level in Childhood ALL.. <i>Blood</i> , 2009, 114, 4705-4705.	1.4	0
155	Long Term Survival and Relapse Rate After Transplantation of Highly T and B Cell Depleted Stem Cells From Alternative Donors in Pediatric Patients with Acute Lymphatic Leukemia.. <i>Blood</i> , 2009, 114, 4333-4333.	1.4	0
156	Improved T Cell Recovery After Transplantation of CD3/CD19 depleted Haploidentical Stem Cell Grafts in Pediatric Patients.. <i>Blood</i> , 2009, 114, 4652-4652.	1.4	0
157	Adoptive Transfer of Hexon-Specific T-Cells as a Treatment of Adenovirus Reactivation Following Allogeneic Stem Cell Transplantation.. <i>Blood</i> , 2009, 114, 796-796.	1.4	1
158	Allogeneic Stem Cell Transplantation for Acquired Aplastic Anemia: Better Outcome with Bone Marrow as Compared to Peripheral Blood in HLA-Matched Sibling Donor Transplantation and Improved Outcome Over Time After Matched Unrelated Donor Transplantation. A Retrospective Analysis of Transplants Reported to the German Registry for Stem Cell Transplantation (DRST).. <i>Blood</i> , 2009, 114, 876-876.	1.4	0
159	Indications and Donor Selections for Allogeneic Stem Cell Transplantation in Children with Hematologic Malignancies. <i>Pediatric Clinics of North America</i> , 2008, 55, 71-96.	1.8	9
160	Immune Response of Human Propagated $\gamma\delta$ -T-Cells to Neuroblastoma Recommend the V β 1+ Subset for $\gamma\delta$ -T-cell-based Immunotherapy. <i>Journal of Immunotherapy</i> , 2008, 31, 896-905.	2.4	28
161	Feasibility and Outcome of Reduced Intensity Conditioning in Haploidentical Transplantation. <i>Annals of the New York Academy of Sciences</i> , 2007, 1106, 279-289.	3.8	66
162	Haploidentical Allogeneic Hematopoietic Cell Transplantation in Adults with CD3/CD19-Depleted Grafts after Reduced-Intensity Conditioning: A Phase I/II Study.. <i>Blood</i> , 2007, 110, 3072-3072.	1.4	0

#	ARTICLE	IF	CITATIONS
163	Hematopoietic Progenitor Cell Transplantation from Parental Donors for Children with Sickle Cell Anemia and Stroke.. Blood, 2007, 110, 3393-3393.	1.4	0
164	The role of graft-versus-host disease in the inhibition of normal B-lymphopoiesis and leukemic control of B-lineage acute lymphocytic leukemia after allogeneic stem cell transplantation. Haematologica, 2006, 91, 292B.	3.5	0
165	Human T Cells From G-CSF-Mobilized Donors Retain Strong Tumoricidal Activity and Produce Immunomodulatory Cytokines After Clinical-Scale Isolation. Journal of Immunotherapy, 2005, 28, 73-78.	2.4	30
166	Inhibitory MHC class I receptors on CD8 ⁺ T cells in tumour immunity and autoimmunity. Trends in Immunology, 2000, 21, 187-191.	7.5	53
167	Pure red cell aplasia. British Journal of Haematology, 2000, 111, 1010-1022.	2.5	73
168	Pure red cell aplasia. British Journal of Haematology, 2000, 111, 1010-1022.	2.5	161
169	Isolation of Highly Purified Autologous and Allogeneic Peripheral CD34 ⁺ Cells Using the CliniMACS Device. Stem Cells and Development, 1999, 8, 209-218.	1.0	129
170	Expression of GD3 disialoganglioside antigen on peripheral T-lymphocytes in patients with disseminated malignant melanoma. Experimental Dermatology, 1997, 6, 64-69.	2.9	2
171	Rapid method for purification of CD56 ⁺ natural killer cells with preferential enrichment of the CD56bright ⁺ subset. Journal of Clinical Laboratory Analysis, 1994, 8, 443-446.	2.1	1
172	Increased susceptibility of ifn- γ -treated neuroblastoma cells to lysis by lymphokine-activated killer cells: Participation of ICAM-1 induction on target cells. International Journal of Cancer, 1991, 47, 527-532.	5.1	58
173	In Vitro Induction of Lymphokine-Activated Killer (Lak) Activity in Patients with Neuroblastoma. Pediatric Hematology and Oncology, 1989, 6, 307-317.	0.8	11
174	Effects of granulocytes on human neuroblastoma cells measured by chemiluminescence and chromium-51 release assay. Luminescence, 1989, 3, 93-96.	0.0	10
175	The role of CD8 ⁺ T cells in the context of allogeneic stem cell transplantation. Exploration of Immunology, 0, , 157-167.	0.3	1